Positive sterility test: investigation and evidence assessment

A positive sterility test requires an investigation, not a reassuring explanation selected in advance. A negative retest does not erase the first result; an organism commonly found in the laboratory does not establish that the product was sterile. The objective is to reconstruct what happened, which evidence supports the conclusion and which products or activities may be affected.

This guide addresses sterility test investigations. Choosing membrane filtration or direct inoculation and establishing method suitability are prerequisites, not shortcuts for interpreting an adverse result.

1. Record the event and contain its impact

Promptly document the observation, sample, container, date, time and person detecting the event. Distinguish confirmed growth, instrument signals and turbidity requiring clarification under the approved method. Involve laboratory management and Quality; batch status and related activities follow applicable procedures, without automatic release.

Protect original records, relevant images, instrument sequences, audit trails and investigation materials. Competent personnel must preserve and manage isolates under biosafety procedures. Do not alter or discard materials before assessing their evidentiary value; record transfers and any limitations on availability.

2. Reconstruct the sample timeline

Connect sampling, transport, receipt, storage, preparation, testing and reading. For each step identify the operator, equipment, consumable, medium batch, environment and original record. Declare missing timestamps: a retrospective reconstruction must not appear to be a contemporaneous record.

Example timeline: observation and notification → protection of samples and data → comparison of the test sequence with environmental records → assessment of hypotheses → conclusion and authorised decision. This is not a schedule of universal deadlines. Assign owners and timing within the quality system, keeping missing information visible.

3. Assess laboratory evidence

Review matrix-specific method suitability, growth promotion, controls, material preparation and storage, incubation conditions, transfers and system integrity. For an isolator also consider gloves, alarms and the biodecontamination cycle. Look for a temporal relationship and plausible mechanism, then determine whether the data demonstrate it.

An alarm recorded after manipulation can mean something different from an integrity failure during the test. A contaminated control requires investigation but is not automatic proof of invalidity: chapter 4 of the FDA Pharmaceutical Microbiology Manual places it in the context of identification and other evidence. Passing controls also have coverage limitations.

4. Identify isolates without equating identity with origin

Preserve the link between isolate and sample, method, raw data, library and result reliability. Species identification is not strain identity. Comparisons using different approaches require caution; an uncertain result must not be forced into the most convenient species assignment.

Section XI.C of FDA Aseptic Processing guidance recommends identification and comparison with monitoring data. Integrate taxonomy with time, location and a contamination pathway. Typing may address a defined question but cannot replace event reconstruction or, by itself, establish the direction of transfer.

5. Extend the investigation to process and product

Do not necessarily wait for a laboratory cause before involving production. Consider sampling, interventions, components, closures, environmental conditions, maintenance, relevant bioburden and other batches with justified connections. Scope must follow possible mechanisms, rather than automatically stopping at one day or batch.

Compare like-for-like trends and justified time windows. Absence of environmental recovery does not prove absence of contamination; an atypical trend alone does not establish causation. Record evidence that contradicts the preferred hypothesis as well.

6. Separate invalidation, retesting and batch disposition

Check the applicable compendial edition, product authorisations and approved procedures. FDA aseptic processing guidance requires conclusive, documented evidence attributing contamination to testing before invalidation. A justified repeat requires a question, rationale and authorisation; repeating until a favourable result appears is testing into compliance.

The 2022 FDA OOS guidance states a scope based on chemistry testing: its retesting schemes must not be mechanically transferred to sterility testing. This article prescribes neither sample numbers nor release rules. Investigation outcome and batch disposition are separate decisions made by authorised functions.

7. Conclude, act and verify effectiveness

Simulated case A. A contemporaneous record documents use of a nonsterile connector during testing. The investigation reconstructs contact with the sample pathway, checks materials and assembles converging evidence on the contamination source. QA assesses invalidation against applicable criteria and impact on other tests using the same material. Correcting the connector alone does not authorise release.

Simulated case B. A species occasionally present in the environment is found, but no entry route is demonstrated. The report retains uncertainty: it neither attributes the result to the laboratory nor invalidates it because of a negative retest. Investigation extends to process, product and connected batches.

The report distinguishes demonstrated cause, contributing factors, excluded hypotheses and limitations. Link each CAPA to the observed problem, with an owner and suitable effectiveness assessment: for example evidence of correct material control and observation of critical operations, rather than a training signature alone. Never invent a root cause to close the file.

Visit the Microbiology and sterility testing hub for related topics.

Sources and access limitations

• FDA, Aseptic Processing, 2004, XI.C: final guidance addressing aseptic manufacture and positive-test investigations.
• FDA, Pharmaceutical Microbiology Manual, revision 02, 25 August 2020, chapter 4: public copy for FDA laboratories; does not replace the pharmacopoeia or approved method.
• European Commission, EU GMP Annex 1, 2022, section 10: testing as part of sterility control.
• USP 〈71〉 and EDQM 2.6.1 and harmonisation status: public records; current full texts not consulted, no specific clause attributed.
• FDA, OOS, May 2022 revision: consulted to define its scope.

Sources checked: 30 September 2026. The matrix and cases are GuideGxP educational examples; they do not replace a site investigation.